Monday, June 30, 2014 9:12:14 AM
IsoRay Announces Its Addition to the Russell Microcap Index
By Market Wire, June 30, 2014, 08:45:00 AM EDT
Vote up A A A
RICHLAND, WA -- (Marketwired) -- 06/30/14 -- IsoRay, Inc. (NYSE MKT:ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for cancers of the brain, lung, head and neck, prostate and gynecologic ("gyn"), today announced that it has been added to the Russell Microcap Index.
Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. Russell determines membership for its equity indexes primarily by objective market-capitalization rankings and style attributes.
IsoRay Chairman and CEO Dwight Babcock commented, "Being included in the Russell Microcap Index represents an important milestone for IsoRay that we expect will increase shareholder awareness of our accomplishments. This follows several other recent milestones for IsoRay, including our newest product, Liquid Cesium-131, being FDA cleared, our first patient being treated using GliaSite with liquid cesium-131 and a peer reviewed publication on the success of using IsoRay's Cesium-131 seed in treating gynecologic cancers."
About Russell
Russell Investments (Russell) is a global asset manager and one of only a few firms that offer activity managed multi-asset portfolios and services that include advice, investments and implementation. Russell stands with institutional investors, financial advisers and individuals working with their advisers -- using the firm's core capabilities that extend across capital market insights, manager research, portfolio construction, portfolio implementation and indexes to help each achieve their desired investment outcomes.
About IsoRay
IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., is the sole producer of Cesium-131 brachytherapy seeds, which
is expanding brachytherapy options throughout the body. Learn more about this innovative Richland, Washington
company and explore the many benefits and uses of GliaSite® and Cesium-131 by visiting www.isoray.com. Join
us on Facebook/Isoray. Follow us on Twitter@Isoray.
Safe Harbor Statement
Statements in this news release about IsoRay's future expectations, including: the advantages of our products and their delivery systems, whether inclusion of IsoRay in the Russell Microcap Index will increase shareholder awareness of IsoRay's accomplishments, and all other statements in this release, other than historical facts, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). This statement is included for the express purpose of availing IsoRay, Inc. of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as physician acceptance, training and use of IsoRay's products, changing levels of demand for IsoRay's current and proposed future products, IsoRay's ability to reduce or maintain expenses while increasing sales, whether additional studies are released and support the conclusions of past studies, patient results achieved with our products, successful completion of future research and development activities, our ability of our distributors and customers to receive and maintain all required regulatory approvals in the U.S. and internationally, continued compliance with ISO standards as audited by BSI, the success of our sales and marketing efforts, IsoRay's ability to successfully manufacture, market and sell its products, whether institutions will receive all required state, federal and foreign regulatory approvals and licenses to use IsoRay's products, IsoRay's ability to manufacture its products in sufficient quantities to meet demand within required delivery time periods while meeting its quality control standards, IsoRay's ability to enforce its intellectual property rights, changes in reimbursement rates, changes in laws and regulations applicable to our products, whether IsoRay will continue to be included in the Russell Microcap Index, and other risks detailed from time to time in IsoRay's reports filed with the SEC.
CONTACT:
IsoRay Medical
Info@Isoray.com
(509) 375-1202
Or
Worldwide Financial
Info@wwfinancial.com
(954) 360-9998
Source: IsoRay, Inc.
This article appears in: News Headlines
Referenced Stocks: ISR
Read more: http://www.nasdaq.com/press-release/isoray-announces-its-addition-to-the-russell-microcap-index-20140630-00418#ixzz367z8LQuj
"Perfection is not attainable, but if we chase perfection we can catch
excellence." Vince Lombardi
Do your research! Play the TA. All posts are my opinion.
Recent CATX News
- Perspective Therapeutics to Participate at Upcoming May Investor Conferences • GlobeNewswire Inc. • 05/03/2024 11:00:00 AM
- Perspective Therapeutics to Provide Recent Business Highlights and Report First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/02/2024 11:00:00 AM
- Perspective Therapeutics Selected by FDA to Participate in the CDRP Program to Expedite Chemistry, Manufacturing, and Controls Development Readiness for VMT-α-NET in NETs • GlobeNewswire Inc. • 04/30/2024 11:00:00 AM
- Perspective Therapeutics to Participate at Upcoming April Investor Conferences • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results • GlobeNewswire Inc. • 03/28/2024 11:30:08 AM
- Perspective Therapeutics Announces Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate [(212)Pb]VMT01 in Combination with Nivolumab in MC1R-Positive Metastatic Melanoma • GlobeNewswire Inc. • 03/18/2024 12:00:00 PM
- Perspective Therapeutics to Host In-Person and Virtual Analyst Day to Discuss Targeted Alpha-Particle Radiotherapy for Cancer on March 18, 2024 • GlobeNewswire Inc. • 03/11/2024 12:00:00 PM
- Perspective Therapeutics Acquires CGMP-Compliant Manufacturing Facility • GlobeNewswire Inc. • 03/05/2024 01:00:00 PM
- Perspective Therapeutics Announces $87.4 Million Private Placement • GlobeNewswire Inc. • 03/04/2024 02:45:00 PM
- Perspective Therapeutics to Participate at Upcoming Investor Conferences • GlobeNewswire Inc. • 02/26/2024 01:00:00 PM
- Perspective Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference • GlobeNewswire Inc. • 02/12/2024 01:00:00 PM
- Perspective Therapeutics Announces Closing of $69.0 Million Public Offering and $20.8 Million Private Placement • GlobeNewswire Inc. • 01/22/2024 09:05:00 PM
- Perspective Therapeutics Announces Pricing of $60.0 Million Public Offering And $20.8 Million Private Placement • GlobeNewswire Inc. • 01/18/2024 12:00:00 PM
- Perspective Therapeutics Announces Proposed Public Offering • GlobeNewswire Inc. • 01/17/2024 09:05:00 PM
- Perspective Commences Recruitment for Second Dose Escalation Cohorts in Clinical Studies of Two Lead Programs: [(212)Pb]VMT-α-NET and [(212)Pb]VMT01 • GlobeNewswire Inc. • 01/17/2024 01:00:00 PM
- Another Healthcare Stock Stealing The Show • AllPennyStocks.com • 01/09/2024 09:10:00 PM
- Perspective Therapeutics Enters into Strategic Agreements with Lantheus Including Equity Investment, Co-Development Options, and Expansion of Manufacturing Capability • GlobeNewswire Inc. • 01/09/2024 01:00:00 PM
- Lantheus Expands Radiopharmaceutical Oncology Pipeline via Strategic Agreements with Perspective Therapeutics • GlobeNewswire Inc. • 01/09/2024 01:00:00 PM
- Perspective Therapeutics Announces Exclusive License Agreement with Mayo Clinic for New Radiopharmaceutical Platform for Prostate Cancer Treatment • GlobeNewswire Inc. • 01/05/2024 01:00:00 PM
- Perspective Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/02/2024 01:00:00 PM
- Perspective Therapeutics Divests Brachytherapy Business • GlobeNewswire Inc. • 12/12/2023 01:00:00 PM
- Perspective Therapeutics Announces First Patient Dosed in a Phase 1 Study of [(212)Pb]VMT-α-NET to Treat Refractory or Relapsed Neuroendocrine Tumors • GlobeNewswire Inc. • 12/07/2023 01:00:00 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM